General and administrative expense also fell 16.7% to $6.5 million, thanks largely to lower commercial planning costs and lower stock-based compensation. Celldex's most important financial metric at this point is its cash position. The …
Celldex Therapeutics Inc.'s stock CLDX, +2.44% plunged 51% in active premarket trade Monday, after an independent panel recommended that the company discontinue the late-stage trial of its brain cancer treatment following …
Unfortunately, varlilumab's results were wholly unimpressive, casting serious doubt on the future of this potential combo moving forward. And while glemba's early-stage results in advanced melanoma were more upbeat with 16% of patients …
Now that we’ve mentioned the most bullish investors, let’s also take a look at some funds that cut their entire stakes in the stock during the third quarter. Interestingly, First Eagle Investment Management cut the biggest position of all the …
It looks like the heavy losses left bruises that the market isn't ready to forget, and the stock has yet to recover. That could change before too long. Celldex has another candidate approaching the finish line, called glemba, that is entirely …
Though Pfizer’s pull out sent Celldex’s stock crashing to a life low, analysts said they were confident the company could advance the vaccine into late-stage trials without a partner. “As much as people are saying that Pfizer didn’t believe in …
Investors drove up the stock price of Celldex Therapeutics more than 20 percent as of noon Thursday on the strength of data for one of its drugs in early-stage development. The drug, CDX-1127, showed success with no safety problems …
Celldex shares were trading down 11.5% to $2.42 on Tuesday. The stock has a 52-week trading range of $2.37 to $5.02 and a consensus analyst price target of $6.50. Shares of Bristol-Myers were last seen down 1% at $51.73, with a …
Here are the highlights from Celldex's first quarter. The nice increase in revenue during the first quarter stemmed …